Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02956382
Recruitment Status : Recruiting
First Posted : November 7, 2016
Last Update Posted : February 8, 2019
Sponsor:
Collaborators:
AbbVie
Pharmacyclics LLC.
Hackensack Meridian Health
Information provided by (Responsible Party):
Georgetown University

Brief Summary:
This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

Condition or disease Intervention/treatment Phase
Refractory Follicular Lymphoma Relapsed Follicular Lymphoma Drug: Ibrutinib Drug: Venetoclax Phase 1 Phase 2

Detailed Description:
In vitro studies of ibrutinib and venetoclax have noted significant cytotoxicity and synergy in mantle cell lymphoma and chronic lymphocytic leukemia cell lines.Data have demonstrated synergy between the two agents in various other B-cell Non-Hodgkin Lymphoma (NHL) cell lines. The investigators theorize that the combination of ibrutinib and venetoclax will provide dual, yet unique, targeted inhibition for patients with follicular lymphoma, resulting in both significant efficacy and less nonspecific toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 41 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Actual Study Start Date : March 1, 2017
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Phase I - Dose Level 0

Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg

Each medication is taken daily. Treatment cycles are 28 days long.

Drug: Ibrutinib
Ibrutinib is dispensed as a capsule.
Other Name: PCI-32765

Drug: Venetoclax
Venetoclax is dispensed as a tablet.
Other Name: ABT-199

Experimental: Phase I - Dose Level 1

Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg

Each medication is taken daily. Treatment cycles are 28 days long.

Drug: Ibrutinib
Ibrutinib is dispensed as a capsule.
Other Name: PCI-32765

Drug: Venetoclax
Venetoclax is dispensed as a tablet.
Other Name: ABT-199

Experimental: Phase I - Dose Level 2

Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg

Each medication is taken daily. Treatment cycles are 28 days long.

Drug: Ibrutinib
Ibrutinib is dispensed as a capsule.
Other Name: PCI-32765

Drug: Venetoclax
Venetoclax is dispensed as a tablet.
Other Name: ABT-199

Experimental: Phase I - Dose Level 3

Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg

Each medication is taken daily. Treatment cycles are 28 days long.

Drug: Ibrutinib
Ibrutinib is dispensed as a capsule.
Other Name: PCI-32765

Drug: Venetoclax
Venetoclax is dispensed as a tablet.
Other Name: ABT-199

Experimental: Phase II Dose
The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
Drug: Ibrutinib
Ibrutinib is dispensed as a capsule.
Other Name: PCI-32765

Drug: Venetoclax
Venetoclax is dispensed as a tablet.
Other Name: ABT-199




Primary Outcome Measures :
  1. Recommended Phase 2 dose [ Time Frame: 18 months ]
    The maximum tolerated dose of Ibrutinib and Venetoclax

  2. Response Rate [ Time Frame: 36 months ]
    Response rate seen in the combination versus 30% response rate for current individual therapies for this group of patients


Secondary Outcome Measures :
  1. Pharmacokinetics of Ibrutinib [ Time Frame: 18 months ]
    Steady-state plasma concentrations of ibrutinib

  2. Pharmacokinetics of Venetoclax [ Time Frame: 18 months ]
    Steady-state plasma concentrations of venetoclax

  3. Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 36 months ]
    Toxicity (attribute and grade) will be summarized for each dose level for all patients who receive at least one dose of study treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Relapsed or refractory, histologically confirmed follicular lymphoma, grade I, II, or IIIa which requires therapy defined by at least one of the following:

    • Constitutional symptoms
    • Cytopenias
  2. High tumor burden (single mass > 7 cm, three masses > 3 cm, symptomatic splenomegaly, organ compression or compromise, ascites, pleural effusion)Must have received at least two prior systemic therapies
  3. All risk by FLIPI 0-5 factors (Appendix I)
  4. Measurable disease Measurable disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptable. Any tumor mass > 1.5 cm is acceptable.

    Lesions that are considered non-measurable include the following:

    • Bone lesions (lesions if present should be noted)
    • Ascites
    • Pleural/pericardial effusion
    • Lymphangitis cutis/pulmonis
    • Bone marrow (involvement by lymphoma should be noted)
  5. Adequate hematologic function independent of transfusion and growth factor support for at least 3 weeks prior to screening unless attributable to disease. Defined as:

    • Absolute neutrophil count (ANC) >1000 cells/mm3 (1.0 x 109/L). ANC > 500 cells/mm3 is permissible if due to disease.
    • Platelet count >50,000 cells/mm3 (50 x 109/L) unless attributable to disease. Platelet count > 20,000 cells/mm3 is permissible if due to disease.
    • Hemoglobin >8.0 g/dL.
  6. Adequate hepatic and renal function defined as:

    • Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 5 is permissible if due to disease.
    • Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin) Bilirubin ≤3 x ULN is permissible if due to disease.
    • Estimated Creatinine Clearance ≥50 ml/min (Cockcroft-Gault based on actual weight)
  7. Prothrombin time (PT)/International normalized ratio (INR) <1.5 x ULN and PTT (aPTT) <1.5 x ULN.
  8. Men and women ≥ 18 years of age.
  9. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. (Appendix II)
  10. Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry.
  11. Male and female subjects who agree to use highly effective methods of birth control (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence, or sterilized partner) during the period of therapy and for 30 days after the last dose of study drug

Exclusion Criteria:

  1. Chemotherapy, monoclonal antibody, or small molecule kinase inhibitor less than or equal 21 days prior to first administration of study treatment
  2. Prior exposure to a Bruton's tyrosine kinase (BTK) or B-cell lymphoma 2 (BCL-2) inhibitor.
  3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or venetoclax.
  4. Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for tumor lysis syndrome.
  5. History of other malignancies, except:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in situ without evidence of disease.
  6. Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration [>14 days] of > 20 mg/day of prednisone) within 28 days of the first dose of study drug.
  7. Undergone an allogeneic stem cell transplant within the past 1 year.
  8. Current or history of graft versus host disease
  9. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
  10. Recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug.
  11. Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade ≤1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia.
  12. Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.
  13. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  14. Known HIV infection
  15. Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).

    • Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, hepatitis C antibody, must have a negative polymerase chain reaction (PCR) result for the respective disease before enrollment. Those who are PCR positive will be excluded.

  16. Any uncontrolled active systemic infection.
  17. Major surgery within 4 weeks of first dose of study drug.
  18. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
  19. Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
  20. Unable to swallow capsules or tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
  21. Concomitant use of warfarin or other Vitamin K antagonists.
  22. Requires treatment with a strong cytochrome P450 CYP3A4/5 inhibitor. (Appendix V)
  23. Richter's transformation confirmed by biopsy.
  24. Malabsorption syndrome or other condition precluding enteral route of administration.
  25. Known Central nervous system (CNS) involvement by lymphoma
  26. Erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome
  27. Lactating or pregnant.
  28. Unwilling or unable to participate in all required study evaluations and procedures.
  29. Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).
  30. Currently active, clinically significant hepatic impairment (greater than or equal moderate hepatic impairment according to the Child Pugh classification (see Appendix IX)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02956382


Locations
Layout table for location information
United States, District of Columbia
Georgetown Lombardi Comprehensive Cancer Center Recruiting
Washington, District of Columbia, United States, 20007
Contact: Pari Ramzi, RN    202-784-0038    ramzip1@georgetown.edu   
Principal Investigator: Bruce Cheson, MD         
United States, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Kara Yannotti, BSN    551-996-5168    Kara.Yannotti@HackensackMeridian.org   
Contact: Sabrina Kdiry, BSN    551-996-5952    Sabrina.Kdiry@HackensackMeridian.org   
Principal Investigator: Lori Ann Leslie, MD         
Sponsors and Collaborators
Georgetown University
AbbVie
Pharmacyclics LLC.
Hackensack Meridian Health
Investigators
Layout table for investigator information
Study Chair: Chaitra Ujjani, MD Seattle Cancer Care Alliance

Layout table for additonal information
Responsible Party: Georgetown University
ClinicalTrials.gov Identifier: NCT02956382     History of Changes
Other Study ID Numbers: 2016-0014
First Posted: November 7, 2016    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Georgetown University:
Ibrutinib
Venetoclax
Follicular
Refractory
Relapsed
Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Follicular
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Venetoclax
Antineoplastic Agents